FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912116772> ?p ?o ?g. }

• W2912116772 abstract "Osteoarthritis (OA) is a common joint disease in the elderly population. Its development has been reported to be associated with cartilage degradation and inflammatory responses. Schisandrin A, a bioactive lignin in Schisandra sphenanthera, has shown its anti-inflammatory potential in various inflammation diseases. However, the effects of Schisandrin A on OA remain to explore. In this study, rat chondrocytes were treated with IL-1β (10ng/ml) with or without different concentrations of Schisandrin A for 24 h. Cell viability was evaluated by CCK-8 assay. Production of nitric oxide (NO) and prostaglandin E2 (PGE2) was measured by the Griess reaction and ELISA. The MAPK/NF-κB-related signaling molecules expression and the protein production of inducible nitic oxide synthase (iNOS), cyclooxygenase (Cox)-2, MMPs (MMP1,MMP3,MMP13), ADAMTS5, Collagen II, aggrecan and Sox9 were detected by Western blot. Protein expression of Collagen II, aggrecan and p65 nuclear translocation was evaluated by immunofluorescence. In vivo, intra-articular injection of 50μM Schisandrin A or equal volume of vehicle was performed on rat OA models. Severity of cartilage damage was evaluated by HE and Safranin-O-Fast green staining. Our results revealed that Schisandrin A could suppress the IL-1β-induced production of NO and PGE2 in rat chodrocytes. Consistent with these findings, the upregulation of iNOS and Cox2 could also been decreased by Schisandrin A. Additionally, Schisandrin A could inhibit IL-1β-induced cartilage matrix catabolic enzymes including MMPs and ADAMTS5. Moreover, the IL-1β-induced downregulation of Collagen II, aggrecan and Sox9 could be ameliorated by Schisandrin A. Mechanistically, Schisandrin A functioned by suppressing MAPK and NF-κB signal pathways. In vivo, Schisandrin A prevented cartilage damage in rat OA model. In conclusion, this study elucidates that Schisandrin A inhibits the IL-1β-induced inflammation and cartilage degradation via suppression of MAPK and NF-κB signal pathways, indicating its potential role in OA therapy." @default.
• W2912116772 created "2019-02-21" @default.
• W2912116772 creator A5017420426 @default.
• W2912116772 creator A5022751868 @default.
• W2912116772 creator A5026405111 @default.
• W2912116772 creator A5030083854 @default.
• W2912116772 creator A5034139107 @default.
• W2912116772 creator A5048167307 @default.
• W2912116772 creator A5059747762 @default.
• W2912116772 creator A5081939866 @default.
• W2912116772 date "2019-01-29" @default.
• W2912116772 modified "2023-10-17" @default.
• W2912116772 title "Schisandrin A Inhibits the IL-1β-Induced Inflammation and Cartilage Degradation via Suppression of MAPK and NF-κB Signal Pathways in Rat Chondrocytes" @default.
• W2912116772 cites W1480259844 @default.
• W2912116772 cites W1815831370 @default.
• W2912116772 cites W1925599086 @default.
• W2912116772 cites W1972987133 @default.
• W2912116772 cites W1982125913 @default.
• W2912116772 cites W1983805610 @default.
• W2912116772 cites W1997027978 @default.
• W2912116772 cites W2005726309 @default.
• W2912116772 cites W2010802338 @default.
• W2912116772 cites W2027400221 @default.
• W2912116772 cites W2030517188 @default.
• W2912116772 cites W2048939600 @default.
• W2912116772 cites W2051725755 @default.
• W2912116772 cites W2062106607 @default.
• W2912116772 cites W2099427592 @default.
• W2912116772 cites W2120312541 @default.
• W2912116772 cites W2124093961 @default.
• W2912116772 cites W2128001125 @default.
• W2912116772 cites W2284187872 @default.
• W2912116772 cites W2397825968 @default.
• W2912116772 cites W2475260528 @default.
• W2912116772 cites W2608899726 @default.
• W2912116772 cites W2747777164 @default.
• W2912116772 cites W2750644092 @default.
• W2912116772 cites W2756924764 @default.
• W2912116772 cites W2765279296 @default.
• W2912116772 cites W2765466053 @default.
• W2912116772 cites W2772784997 @default.
• W2912116772 cites W2788764162 @default.
• W2912116772 cites W2801801034 @default.
• W2912116772 cites W2894191756 @default.
• W2912116772 cites W4211069396 @default.
• W2912116772 doi "https://doi.org/10.3389/fphar.2019.00041" @default.
• W2912116772 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6361757" @default.
• W2912116772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30761007" @default.
• W2912116772 hasPublicationYear "2019" @default.
• W2912116772 type Work @default.
• W2912116772 sameAs 2912116772 @default.
• W2912116772 citedByCount "51" @default.
• W2912116772 countsByYear W29121167722019 @default.
• W2912116772 countsByYear W29121167722020 @default.
• W2912116772 countsByYear W29121167722021 @default.
• W2912116772 countsByYear W29121167722022 @default.
• W2912116772 countsByYear W29121167722023 @default.
• W2912116772 crossrefType "journal-article" @default.
• W2912116772 hasAuthorship W2912116772A5017420426 @default.
• W2912116772 hasAuthorship W2912116772A5022751868 @default.
• W2912116772 hasAuthorship W2912116772A5026405111 @default.
• W2912116772 hasAuthorship W2912116772A5030083854 @default.
• W2912116772 hasAuthorship W2912116772A5034139107 @default.
• W2912116772 hasAuthorship W2912116772A5048167307 @default.
• W2912116772 hasAuthorship W2912116772A5059747762 @default.
• W2912116772 hasAuthorship W2912116772A5081939866 @default.
• W2912116772 hasBestOaLocation W29121167721 @default.
• W2912116772 hasConcept C104317684 @default.
• W2912116772 hasConcept C105702510 @default.
• W2912116772 hasConcept C109523444 @default.
• W2912116772 hasConcept C127561419 @default.
• W2912116772 hasConcept C142724271 @default.
• W2912116772 hasConcept C167814343 @default.
• W2912116772 hasConcept C178790620 @default.
• W2912116772 hasConcept C185592680 @default.
• W2912116772 hasConcept C197534660 @default.
• W2912116772 hasConcept C204787440 @default.
• W2912116772 hasConcept C2776164576 @default.
• W2912116772 hasConcept C2776224515 @default.
• W2912116772 hasConcept C2777622882 @default.
• W2912116772 hasConcept C2780550940 @default.
• W2912116772 hasConcept C2781013607 @default.
• W2912116772 hasConcept C3020332539 @default.
• W2912116772 hasConcept C519581460 @default.
• W2912116772 hasConcept C55493867 @default.
• W2912116772 hasConcept C55728118 @default.
• W2912116772 hasConcept C71924100 @default.
• W2912116772 hasConcept C86803240 @default.
• W2912116772 hasConcept C95444343 @default.
• W2912116772 hasConcept C98274493 @default.
• W2912116772 hasConceptScore W2912116772C104317684 @default.
• W2912116772 hasConceptScore W2912116772C105702510 @default.
• W2912116772 hasConceptScore W2912116772C109523444 @default.
• W2912116772 hasConceptScore W2912116772C127561419 @default.
• W2912116772 hasConceptScore W2912116772C142724271 @default.
• W2912116772 hasConceptScore W2912116772C167814343 @default.
• W2912116772 hasConceptScore W2912116772C178790620 @default.
• W2912116772 hasConceptScore W2912116772C185592680 @default.
• W2912116772 hasConceptScore W2912116772C197534660 @default.
• W2912116772 hasConceptScore W2912116772C204787440 @default.

• next